Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Juno Therapeutics

Biotech & Life Sciences · Seattle, United States · Founded 2013 · IPO 2014 Unicorn

Is a clinical-stage company, develops immunotherapies for the treatment of cancer

Valuation
$9.00B
Market cap · 2026
Revenue
$112M
Latest reported FY

Investors

4 investors on Juno Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage

Global footprint

Where Juno Therapeutics has talent and traffic

Workforce by country
4 countries with
team presence
🇺🇸 United States95.2%
🇨🇭 Switzerland1.6%
🇩🇪 Germany1.6%
🇦🇺 Australia1.6%
4 countries shown
Web traffic by country
710 monthly visits
across markets
🇺🇸 United States98.6%
Top 1 markets shown

Patent intelligence

$239M patent portfolio · 149 active families

Estimated portfolio value
$239M
2.7% of market cap · comparable to top peer Celularity ($195M)
149 active patent families
Where Juno Therapeutics innovates Cell biologyCell therapyBiophysicsCell sheetLymphocyte

Where Juno Therapeutics concentrates vs peers

Each axis is a top-10 topic across Juno Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Juno Therapeutics's 6 investments and acquisitions.

Every disclosed deal where Juno Therapeutics appeared as a backer or acquirer, 2015–2020. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

6 deals across Juno Therapeutics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Juno Therapeutics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        6 of 6 deals

        Market sentiment

        What the market is saying about Juno Therapeutics

        An AI-synthesized read of the highest-engagement posts about Juno Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Juno Therapeutics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.